Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03647137 · ClinicalTrials.gov registry record
Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD
A clinical trial, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 53
- Enrollment target
NCT03647137: Completed study, sponsored by VA Office of Research and Development.
NCT03647137 is a clinical trial that has completed, run by VA Office of Research and Development. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03647137 has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
Study Summary
Early stage Parkinson disease (PD) is characterized by a 'honeymoon' phase in terms of responsiveness of motor symptoms, including gait, to dopaminergic pharmacotherapy. Advancing PD is associated with disabling axial motor complications, such as freezing of gait (FoG), with decreased or even refractory dopamine responsiveness in over 50% of patients. The management of dopamine resistant gait problems represents the most important unmet need in PD. This study will related detailed motor testing to brain PET imaging to see if certain molecules (or lack thereof) involved with neurologic transmission in the brain are involved with FoG.
Interventions
- OTHER Detailed motor testing, including FoG, in PD subjects
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2016-06-07 |
| Est. Completion | 2021-05-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03647137
The ClinicalTrials.gov registry entry for NCT03647137 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Detailed motor testing, including FoG, in PD subjects is the first listed.
NCT03647137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03647137 about?
NCT03647137 is a clinical study titled "Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD". Early stage Parkinson disease (PD) is characterized by a 'honeymoon' phase in terms of responsiveness of motor symptoms, including gait, to dopaminergic pharmacotherapy. Advancing PD is associated with disabling axial motor complications, such as freezing of gait (FoG), with decreased or even refrac...
What is the current status of trial NCT03647137?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2016-06-07. Estimated completion is 2021-05-26.
What interventions are being tested in trial NCT03647137?
The interventions under investigation include: Detailed motor testing, including FoG, in PD subjects (OTHER).
Who is sponsoring clinical trial NCT03647137?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.